Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation’s annual Familial Hypercholesterolemia (FH) Awareness Day.
Chief Executive Officer Mary Szela said, "On FH Awareness Day, we are proud to stand with The FH Foundation and support their mission of increasing awareness of FH, including homozygous FH (HoFH), a very serious and often undiagnosed disease. Education and awareness help to support early diagnosis and treatment, and ultimately make an impact for individuals and families who are impacted by this disease.”
FH is a genetic condition that impacts the body’s ability to remove cholesterol that the body naturally produces. As a result, blood cholesterol levels are significantly elevated. There are two forms of the disease: heterozygous FH (HeFH), in which the genetic defect causing the impairment is inherited from one parent; and HoFH, in which the genetic defect is inherited from both parents. HoFH is the most severe form of the disorder.
Established in 2012, FH Awareness Day is a campaign initiated by the FH Foundation to raise awareness of FH in the general public. This annual event is held during National Cholesterol Education Month.
To learn more about familial hypercholesterolemia, visit www.thefhfoundation.org.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
[email protected]
